Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse

Diabetes and Vascular Disease Research

Volumn 7, Issue 3, 2010, Pages 231-238

  Imran, S A ^a,b   Brown, R E ^a   Wilkinson, M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Division of Endocrinology and Metabolism   (Canada)

Author keywords

Adipokines; ARB; Diabetes; Valsartan

Indexed keywords

ADIPOCYTOKINE; MESSENGER RNA; RESISTIN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFECT; FASTING INDUCED ADIPOSE FACTOR GENE; GENE EXPRESSION; HYPOPHYSIS; HYPOTHALAMUS; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MALE; MOUSE; MOUSE STRAIN; MOUSE STRAIN OB OB; NONHUMAN; RESISTIN GENE; SUBCUTANEOUS FAT; TREATMENT DURATION;

ANGIOPOIETINS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CEREBRAL CORTEX; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYPOTHALAMUS; INTRA-ABDOMINAL FAT; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PITUITARY GLAND; RESISTIN; RNA, MESSENGER; SUBCUTANEOUS FAT; TETRAZOLES; TIME FACTORS; VALINE;

EID: 79551718514     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164110369848     Document Type: Article

References (59)

1. Scheen, A.J. (2004 b) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30: 498-505. (Pubitemid 40073639)
2. Scheen, A.J. (2004 a) Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 64: 2537-65. (Pubitemid 39591650)
3. Chu, K.Y., Leung, P.S. (2009) Angiotensin II in type 2 diabetes mellitus. Curr Protein Pept Sci 10 (1). 75-84.
4. Shiuchi, T., Iwai, M., Li, H.S., et al. (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-10. (Pubitemid 38579905)
5. Yusuf, S., Gerstein, H., Hoogwerf, B., et al. (2001) Ramipril and the development of diabetes. JAMA 286: 1882-5. (Pubitemid 33010241)
6. Dahlöf, B., Devereux, R.B., Kjeldsen, S.E., et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). a randomised trial against atenolol. Lancet 359: 995-1003. (Pubitemid 34286536)
7. Vermes, E., Ducharme, A., Bourassa, M.G., et al. (2003) Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 107: 1291-6. (Pubitemid 36314413)
8. Yusuf, S., Ostergren, J.B., Gerstein, H.C., et al. (2005) Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 112 (1). 48-53. (Pubitemid 40962568)
9. Kjeldsen, S.E., Julius, S., Mancia, G., et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24: 1405-12. (Pubitemid 43948341)
10. Elliott, W.J., Meyer, P.M. (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201-7. (Pubitemid 46111014)
11. Abuissa, H., Bel, D.S., O'Keefe, J.H. Jr. (2005) Strategies to prevent type 2 diabetes. Curr Med Res Opin 21: 1107-14. (Pubitemid 41032702)
12. Abuissa, H., Jones, P.G., Marso, S.P., O'Keefe, J.H. Jr. (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomised clinical trials. J Am Coll Cardiol 46: 821-6. (Pubitemid 41224805)
13. Brown, R.E., Imran, S.A., Wilkinson, M. In: Preedy, V.R. (ed). Handbook of Behaviour, Diet and Nutrition. Springer. In Press.
14. Fowler, J.D., Krueth, S.B., Bernlohr, D.A., Katz, S.A. (2009) Renin dynamics in adipose tissue: adipose tissue control of local renin concentrations. Am J Physiol Endocrinol Metab 296: E343-50.
15. Schling, P., Mallow, H., Trindl, A., Löffler, G. (1999) Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord 23: 336-41. (Pubitemid 29182390)
16. Mallow, H., Trindl, A., Löffler, G. (2000) Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm Metab Res 32: 500-3. (Pubitemid 32176077)
17. Fogari, R., Zoppi, A. (2005) Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant ? Am J Cardiovasc Drugs 5: 211-23. (Pubitemid 40994264)
18. Kawamura, T., Yoshida, K., Sugawara, A., et al. (2002) Impact of exercise and angiotensin-converting enzyme inhibition on tumor necrosis factor-alpha and leptin in fructose-fed hypertensive rats. Hypertens Res 25: 919-26. (Pubitemid 36024649)
19. Umeda, M., Kanda, T., Murakami, M. (2003) Effects of angiotensin II receptor antagonists on insulin resistance syndrome and leptin in sucrose-fed spontaneously hypertensive rats. Hypertens Res 26: 485-92. (Pubitemid 36849730)
20. Mathai, M.L., Naik, S., Sinclair, A.J., Weisinger, H.S., Weisinger, R.S. (2008) Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) 32: 1576-84.
21. Nielsen, S., Lihn, A.S., Stergaard, T., Mogensen, C.E., Schmitz, O. (2004) Increased plasma adiponectin in losartan-treated type 1 diabetic patients. a mediator of improved insulin sensitivity? Horm Metab Res 36 (3). 194-6. (Pubitemid 38510043)
22. Furuhashi, M., Ura, N., Higashiura, K., et al. (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 (1). 76-81. (Pubitemid 36842239)
23. Nomura, S., Shouzu, A., Omoto, S., et al. (2006) Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 117: 385-92. (Pubitemid 43197489)
24. Trayhurn, P., Wood, I.S. (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92: 347-55. (Pubitemid 40277057)
25. Hauner, H. (2005) Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 64 (2). 163-9. (Pubitemid 40813538)
26. Trayhurn, P. (2005) Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 184: 285-93. (Pubitemid 41039735)
27. Steppan, C.M., Lazar, M.A. (2004) The current biology of resistin. J Intern Med 255: 439-47. (Pubitemid 38446357)
28. McTernan, P.G., Kusminski, C.M., Kumar, S. (2006) Resistin. Curr Opin Lipidol 17 (2). 170-5.
29. Oike, Y., Akao, M., Kubota, Y., Suda, T. (2005) Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med 11: 473-9. (Pubitemid 41415727)
30. Xu, A., Lam, M.C., Chan, K.W., et al. (2005) Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci U S A 102: 6086-91. (Pubitemid 40594259)
31. Hato, T., Tabata, M., Oike, Y. (2008) The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 18 (1). 6-14.
32. Morash, B.A., Ur, E., Wiesner, G., Roy, J., Wilkinson, M. (2004) Pituitary resistin gene expression: effects of age, gender and obesity. Neuroendocrinology 79 (3). 149-56. (Pubitemid 38581689)
33. Kersten, S., Mandard, S., Tan, N.S., Escher, P., Metzger, D., Chambon, P. (2000) Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 275: 28488-93.
34. Wiesner, G., Morash, B.A., Ur, E., Wilkinson, M. (2004) Food restriction regulates adipose-specific cytokines in pituitary gland but not in hypothalamus. J Endocrinol 180 (3). R1-6. (Pubitemid 38443403)
35. Wilkinson, M., Brown, R., Imran, S.A., Ur, E. (2007) Adipokine gene expression in brain and pituitary gland. Neuroendocrinology; 86 (3). 191-209. (Pubitemid 350073607)
36. Tomono, Y., Iwai, M., Inaba, S., Mogi, M., Horiuchi, M. (2008) Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 21 (2). 206-12. (Pubitemid 351231578)
37. Wiesner, G., Brown, R.E., Robertson, G.S., Imran, S.A., Ur, E., Wilkinson, M. (2006) Increased expression of the adipokine genes resistin and fasting-induced adipose factor in hypoxic/ischaemic mouse brain. Neuroreport 17: 1195-8. (Pubitemid 44051412)
38. Yoon, J.C., Chickering, T.W., Rosen, E.D., et al. (2000) Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 20: 5343-9. (Pubitemid 30431587)
39. Ge, H., Cha, J.Y., Gopal, H., et al. (2005) Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 46: 1484-90. (Pubitemid 43109813)
40. Brown, R., Imran, S.A., Ur, E., Wilkinson, M. (2008) Valproic acid and CEBPalpha-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes. Neuroendocrinology 88 (1). 25-34. (Pubitemid 352009116)
41. Dutton, S., Trayhurn, P. (2008) Regulation of angiopoietin-like protein 4/fasting-induced adipose factor (Angptl4/FIAF) expression in mouse white adipose tissue and 3T3-L1 adipocytes. Br J Nutr 100 (1). 18-26.
42. Atzmon, G., Yang, X.M., Muzumdar, R., Ma, X.H., Gabriely, I., Barzilai, N. (2002) Differential gene expression between visceral and subcutaneous fat depots. Horm Metab Res 34: 622-8. (Pubitemid 36398696)
43. Vidal, H. (2001) Gene expression in visceral and subcutaneous adipose tissues. Ann Med 33: 547-55. (Pubitemid 33052276)
44. Hong, S.J., Shim, W.J., Choi, J.I., et al. (2007) Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 100: 1625-9. (Pubitemid 350122328)
45. Yilmaz, M.I., Sonmez, A., Caglar, K., et al. (2007) Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton. 12 (2). 147-53. (Pubitemid 46426854)
46. Usui, I., Fujisaka, S., Yamazaki, K., et al. (2007) Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 77 (2). 210-4. (Pubitemid 46670421)
47. Sonmez, A., Kisa, U., Uckaya, G., et al. (2001) Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. J Renin Angiotensin Aldosterone Syst 2 (2). 12-6.
48. Aksnes, T.A., Seljeflot, I., Torjesen, P.A., Höieggen, A., Moan, A., Kjeldsen, S.E. (2007) Improved insulin sensitivity by the angiotensin II receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 56: 1470-7. (Pubitemid 47562496)
49. Kim, S., Soltani-Bejnood, M., Quignard-Boulange, A., Massiera, F., Teboul, M., Ailhaud, G. (2006) The adipose Renin-Angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal Renin-Angiotensin system. J Biomed Biotechnol 2006: 27012.
50. Massiéra, F., Bloch-Faure, M., Ceiler, D., Murakami, K., Fukamizu, A., Gasc, J.M. (2001) Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15: 2727-9.
51. Jones, B.H., Standridge, M.K., Moustaid, N. (1997) Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 138: 1512-9. (Pubitemid 27137101)
52. Sugimoto, K., Qi, N.R., Kazdová, L., Pravenec, M., Ogihara, T., Kurtz, T.W. (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1003-9. (Pubitemid 44297575)
53. Crandall, D.L., Herzlinger, H.E., Saunders, B.D., Armellino, D.C., Kral, J.G. (1994) Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res 35: 1378-85. (Pubitemid 24251032)
54. Way, J.M., Görgün, C.Z., Tong, Q., et al. (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276: 25651-3.
55. Rajala, M.W., Qi, Y., Patel, H.R., Takahashi, N., Banerjee, R., Pajvani, U.B. (2004) Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53: 1671-9. (Pubitemid 38857023)
56. Krusinová, E., Klementová, M., Kopecký, J., et al. (2007) Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects. Eur J Endocrinol 157: 443-9. (Pubitemid 350018447)
57. Erbe, D.V., Gartrell, K., Zhang, Y.L., et al. (2006) Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45 (3). 154-62. (Pubitemid 44716729)
58. Ahima, R.S., Osei, S.Y. (2008) Adipokines in obesity. Front Horm Res 36: 182-97.
59. Delporte, M.L., El Mkadem, S.A., Quisquater, M., Brichard, S.M. (2004) Leptin treatment markedly increased plasma adiponectin but barely decreased plasma resistin of ob/ob mice. Am J Physiol Endocrinol Metab 287: E446-53.